ArticleMaterials today. Bio2026
A dual-responsive CO-releasing nanogel ameliorates retinal ischemia-reperfusion injury by restoring mitochondrial homeostasis and attenuating cGAS-STING pathway activation.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal ischemia-reperfusion injury (RIRI) represents a central pathological mechanism underlying neurodegeneration in multiple blinding ocular diseases, including glaucoma, diabetic retinopathy, and retinal vein occlusion. Ischemic stress triggers a surge of reactive oxygen species (ROS) within retinal ganglion cells, leading to mitochondrial dysfunction and initiating a vicious cycle of cellular damage. Targeting the regulation of redox balance within the RIRI microenvironment to restore mitochondrial homeostasis remains a major challenge in RIRI therapy. Here, a dual ROS-responsive carbon monoxide (CO) prodrug nanoplatform (COPN) was developed. This system integrates a ROS-sensitive CO-releasing molecule, CORM401, as the active prodrug unit, which is encapsulated within a disulfide-crosslinked dendritic nanogel matrix, thereby enabling site-specific CO release under pathological oxidative conditions. Locally released CO effectively neutralizes excessive ROS, restores mitochondrial quality control, and prevents mitochondrial DNA cytosolic leakage, thereby attenuating cGAS-STING pathway activation and subsequent neuroinflammatory responses. Furthermore, COPN successfully reverses ischemia-induced immunometabolic dysregulation, restores oxidative phosphorylation capacity, and enhances cellular metabolic resilience. This study offers a promising therapeutic strategy with strong translational potential for treating oxidative retinal diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.